Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: The novel anti-inflammatory activity of mcIRBP from Momordica charantia is associated with the improvement of diabetic nephropathy
Pei-Yung
Liao
ab,
Hsin-Yi
Lo
a,
I-Chen
Liu
a,
Lun-Chien
Lo
c,
Chien-Yun
Hsiang
*d and
Tin-Yun
Ho
*ae
aGraduate Institute of Chinese Medicine, China Medical University, Taichung 40402, Taiwan. E-mail: tyh@mail.cmu.edu.tw
bDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan
cSchool of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
dDepartment of Microbiology and Immunology, China Medical University, Taichung 40402, Taiwan. E-mail: cyhsiang@mail.cmu.edu.tw
eDepartment of Health and Nutrition Biotechnology, Asia University, Taichung 41354, Taiwan
First published on 26th January 2022
Abstract
Correction for ‘The novel anti-inflammatory activity of mcIRBP from Momordica charantia is associated with the improvement of diabetic nephropathy’ by Pei-Yung Liao et al., Food Funct., 2022, DOI: 10.1039/d1fo03620c.
The authors regret that an incorrect patent number was shown in the footnotes of the original article. The corrected footnote should read:
Patent application for mcIRBP have been approved by Taiwan Patent Office (I588153), Japan Patent Office (JP 5676538), US Patent Office (US 8697649 B2), Europe Patent Office (EP 2664622 B1), and China Patent Office (ZL 201210164364.4).
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2022 |